PD-1/CXCR6CD8T lymphocytes promote MASLD malignant progression through inflammatory and immune dysregulation.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to hepatocellular carcinoma (HCC), but the role of CD8 T cells from MASLD to HCC progression is unclear. This study investigates the dynamic changes in CD8 T cells via MASLD malignancy to analyzing underlying mechanisms using animal models and clinical validation. MASLD model mice were fed with a high-fat diet (HFD) or HFD plus 2-fluorene-acetylamino (HFD/HCC). Model livers exhibited lipid accumulation with high triglyceride, cholesterol and low-density lipoprotein, and hepatocyte damages (ALT & AST, P < 0.001). During MASLD progression, the alterations of CD8 T, PD-1 CD8 T and CXCR6CD8 T cells analyzed by flow cytometry showed intrahepatic CD8 T cell ratio decreased while PD-1 and CXCR6 subsets significantly increased (P < 0.05) in the HFD/HCC group. Hepatic cells by single-cell sequencing revealed CD8 T cells interacting with Kupffer/neutrophil cells and contributing to inflammation and immune dysfunction. Clinical samples from MASLD/HCC patients confirmed the higher ratios of CD8T, PD-1CD8 T, and CXCR6CD8 T cells in HCC patients with MASLD, accompanied by lipid metabolism abnormalities and hepatocyte injury. These findings demonstrated that decreased CD8 T cells, particularly increased PD-1/CXCR6 subsets, could drive MASLD malignancy via inflammatory and immune dysregulation, highlighting potential targets for MASLD immunotherapy.